HealthWarehouse.com, Inc (HEWA) Fair Value & Analysis

Healthcare · US · Market cap $8.5M

A solid business, but screening 17% overvalued on our models.

What matters now

• Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
• Our model range runs from $0.0800 (bear) to $0.1300 (bull), base $0.1000. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 55/100 (solid quality) with high evidence: the data supports the verdict.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.

How to read this chart

60‑month range $0.0700 – $0.2700 · fair‑value band $0.0800 – $0.1300 · the $0.1200 price screens above the $0.1000 fair value. Dashed = 300-day average. As of Jul 29, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

HealthWarehouse.com, Inc (HEWA) currently trades at $0.1200, while our model-based Fair Value estimate is $0.1000, implying the stock looks roughly 16.7% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, HealthWarehouse.com, Inc generated revenue of $40.3M at a net margin of -0.7%. Revenue declined 57.8% year over year. Net debt stands at $1.1M. Fundamentals as of Jul 29, 2026

Our scenario range runs from $0.0800 (bear case) to $0.1300 (bull case); at $0.1200, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 33% below its 52-week high and 50% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -17%, HEWA screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models ($0.2300) versus Economic Profit ($0.0500). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

HealthWarehouse.com, Inc. operates an online and mail order pharmacy. It offers pharmacy supplies; diabetic supplies that include test strips, glucose meters, insulin syringes, and pen needles; over-the-counter products, such as products for allergy and sinus, diet and nutrition, digestive health, hair care, pain and fever, and personal care; home medical …

Full company description

HealthWarehouse.com, Inc. operates an online and mail order pharmacy. It offers pharmacy supplies; diabetic supplies that include test strips, glucose meters, insulin syringes, and pen needles; over-the-counter products, such as products for allergy and sinus, diet and nutrition, digestive health, hair care, pain and fever, and personal care; home medical products; and pet supplies, which include flea and tick products, drugs for pets, and interceptors. The company sells prescription medications and OTC products to individual consumers over the Internet. HealthWarehouse.com, Inc. was founded in 2007 and is headquartered in Florence, Kentucky.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

HealthWarehouse.com, Inc reported revenue of $49.0M in FY2025 versus $16.1M in FY2021, a compound +32.0%/yr. Reported net income was $265K in FY2025.

HEWA screens 17% overvalued. Compare with JD Health International Inc →

Peer Group

Pharmaceutical Retailers · 61 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Pharmaceutical Retailers median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.